SGLT2 inhibitors have been widely studied as a promising therapeutic [54]: dapagliflozin (farxiga) is an FDA approved therapeutic for CKD that inhibits SGLT2 function and blocks reabsorption of glucose into cells [51,54]. The gene discussed is SLC5A2; the disease is chronic kidney disease.